Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phas...
May 13 2019 - 4:16PM
Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company
focused on developing and commercializing innovative therapies for
women’s health and prostate cancer, today announced it will hold a
webcast and conference call beginning at 8:30 a.m. Eastern Time /
5:30 a.m. Pacific Time on Tuesday, May 14th 2019 to discuss results
from the Phase 3 LIBERTY 1 study of once daily relugolix
combination therapy in women with uterine fibroids and heavy
menstrual bleeding.
Webcast/Teleconference DetailsTo participate in
the live conference call, please dial 1-866-807-9684 for domestic
callers and 1-412-317-5415 for international callers. A live
webcast of the conference call will also be available on the
investor relations page of Myovant’s website at
investors.myovant.com. After the live webcast, the event will
remain archived on the Myovant website for at least 30 days.
About Myovant Myovant Sciences aspires to be
the leading healthcare company focused on innovative treatments for
women's health and prostate cancer. Myovant's lead product
candidate is relugolix, an oral, once daily small molecule that
acts as a GnRH receptor antagonist. Myovant has three late-stage
clinical programs for relugolix ongoing in uterine fibroids,
endometriosis and prostate cancer. Myovant is also developing
MVT-602, an oligopeptide kisspeptin-1 receptor agonist, and has
completed a Phase 2a study for the treatment of female infertility
as part of assisted reproduction. Roivant Sciences is the majority
owner of Myovant. Takeda Pharmaceuticals International AG granted
Myovant an exclusive, worldwide license to develop and
commercialize relugolix (excluding Japan and certain
other Asian countries) and an exclusive license to develop and
commercialize MVT-602 in all countries worldwide. Over time,
Myovant intends to expand its development pipeline to include other
potential treatments for women's health and prostate cancer. For
more information, please visit Myovant's website
at www.myovant.com. Follow @Myovant on Twitter and LinkedIn
(https://www.linkedin.com/myovantsciences).
Investor Contact: Frank Karbe Chief Financial
Officer Myovant Sciences, Inc. investors@myovant.com
Media Contact: Sheryl Seapy Pure Communications
sseapy@w2ogroup.com 949.903.4750
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024